DOCSLIB.ORG

For Peer Review Only

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Peer Review Only Critical Reviews in Toxicology For Peer Review Only Workshop Report: Putative Adverse Ou tcome Pathways (AOP) Relevant to Neurotoxicity Journal: Critical Reviews in Toxicology Manuscript ID: Draft Manuscript Type: Review Date Submitted by the Author: n/a Complete List of Authors: Price, Anna; European Commission Joint Research Centre, Institute for Health and Consumer Protection Crofton, Kevin; US Environmental Protection Agency, Sachana, Magdalini; European Commission Joint Research Centre, Institute for Health and Consumer Protection Shafer, Timothy; USEPA, Behl, Mamta; National Institute of Environmental Health Sciences, Forsby, Anna; Department of Neurochemistry, Stockholm University, Hargreaves, Alan; Nottingham Trent University, Nottingham, Landesmann, Brigitte; European Commission Joint Research Centre, Lein, Pamela; School of Veterinary Medicine, University of California Davis, Department of Molecular Biosciences Louisse, Jochem; European Commission Joint Research Centre, Monnet-Tschudi, Florianne; University of Lausanne, Paini, Alicia; European Commission Joint Research Centre, Rolaki, Alexandra; European Commission Joint Research Centre, Schrattenholz, André; ProteoSys AG Mainz, Suñol, Cristina; Institut d’Investigacions Biomèdiques de Barcelona, van Thriel, Christoph; IfADo-Leibniz Research Center for Working Environment and Human Factors, Whelan, Maurice; European Commission Joint Research Centre, Institute for Health and Consumer Protection Fritsche, Ellen; Leibniz Research Institute for Environmental Medicine, Keywords: pathways of neurotoxicity, key events, adverse outcome , in vitro testing, URL: http://mc.manuscriptcentral.com/btxc Email: [email protected] Page 1 of 172 Critical Reviews in Toxicology 1 2 3 4 predictive toxicology 5 6 7 8 9 10 11 12 13 14 For Peer Review Only 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 URL: http://mc.manuscriptcentral.com/btxc Email: [email protected] Critical Reviews in Toxicology Page 2 of 172 1 2 3 Workshop Report: Putative Adverse Outcome Pathways (AOP) Relevant to Neurotoxicity 4 5 6 7 1 2 1 2 3 8 Anna Bal-Price , Kevin M.Crofton , Magdalini Sachana , Timothy J. Shafer , Mamta Behl , 4 5 1 6 1 9 Anna Forsby , Alan Hargreaves , Brigitte Landesmann , Pamela J. Lein , Jochem Louisse , 10 Florianne Monnet-Tschudi 7, Alicia Paini 1, Alexandra Rolaki 1, André Schrattenholz 8, Cristina 11 9 10 1 11 12 Suñol , Christoph van Thriel , Maurice Whelan and Ellen Fritsche 13 14 For Peer Review Only 15 1 16 Joint Research Centre of the European Commission, Institute for Health and Consumer 17 Protection, Ispra, Italy; 2National Center for Computational Toxicology, Office of 18 Research and Development, U.S. Environmental Protection Agency, RTP, NC 27711, 19 3 20 USA; Division of the National Toxicology Program, National Institute of Environmental 21 Health Sciences, Research Triangle Park, NC, USA; 4 Department of Neurochemistry, 22 Stockholm University, Sweden; 5Nottingham Trent University, Nottingham, UK; 23 6 24 Department of Molecular Biosciences, School of Veterinary Medicine, University of 25 California Davis, Davis, California, USA; 7Department of Physiology and SCAHT, 26 8 27 University of Lausanne, Lausanne, Switzerland; ProteoSys AG, Mainz, Germany; 9 28 Institut d’Investigacions Biomèdiques de Barcelona. IIBB-CSIC. IDIBAPS. CIBERESP, 29 Barcelona, Spain; 10IfADo-Leibniz Research Center for Working Environment and 30 11 31 Human Factors, Dortmund, Germany; IUF - Leibniz Research Institute for 32 Environmental Medicine, Düsseldorf, Germany 33 34 35 36 37 38 Corresponding author: 39 40 Dr Anna K. Bal-Price 41 Systems Toxicology Unit 42 EURL- ECVAM 43 44 Institute for Health and Consumer Protection, 45 European Commission, 46 Joint Research Centre, TP 580 47 Via Fermi 1, 21026 Ispra (VA), Italy 48 Tel.: +39 0332 78 6018 49 50 Fax: +39 0332 78 5336 51 Email: [email protected] 52 53 54 55 56 57 58 59 60 1 URL: http://mc.manuscriptcentral.com/btxc Email: [email protected] Page 3 of 172 Critical Reviews in Toxicology 1 2 3 Abstract 4 5 6 The Adverse Outcome Pathway (AOP) framework provides a template that facilitates 7 8 understanding of complex biological systems and the pathways of toxicity that result in adverse 9 10 11 outcomes (AOs). The AOP starts with an molecular initiating event (MIE) in which a chemical 12 13 interacts with a biological target(s), followed by a sequential series of KEs, which are cellular, 14 For Peer Review Only 15 anatomical and/or functional changes in biological processes, that ultimately result in an AO 16 17 18 manifest in individual organisms and populations. It has been developed as a tool for a 19 20 knowledge-based safety assessment that relies on understanding mechanisms of toxicity, rather 21 22 than simply observing its adverse outcome. 23 24 25 A large number of cellular and molecular processes are known to be crucial to proper 26 27 development and function of the central (CNS) and peripheral nervous systems (PNS). However, 28 29 there are relatively few examples of well-documented pathways that include causally linked 30 31 32 MIEs and KEs that result in adverse outcomes in the CNS or PNS. As a first step in applying the 33 34 AOP framework to adverse health outcomes associated with exposure to exogenous neurotoxic 35 36 37 substances, the EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) 38 39 organized a workshop (March 2013, Ispra, Italy) to identify potential AOPs relevant to 40 41 neurotoxic and developmental neurotoxic outcomes. Although the AOPs outlined during the 42 43 44 workshop are not fully described, they could serve as a basis for further, more detailed AOP 45 46 development by further identification of data gaps and application of modified Bradford-Hill 47 48 criteria (Meek et al., 2014) to be useful for human health risk assessment. 49 50 51 52 53 54 55 Key words: pathways of neurotoxicity, molecular initiating event, key events, adverse outcome 56 57 pathway, in vitro testing, predictive toxicology 58 59 60 2 URL: http://mc.manuscriptcentral.com/btxc Email: [email protected] Critical Reviews in Toxicology Page 4 of 172 1 2 3 4 Table of Contents 5 6 7 Introduction to AOP concept ........................................................................................................................ 4 8 9 Challenges for neurotoxicity AOP development .......................................................................................... 7 10 11 Common key events for neurotoxic outcomes .............................................................................................. 9 12 Considering life stage-specific susceptibility in neurotoxicity AOPs ......................................................... 12 13 14 Future directionsFor for development Peer of Neurotoxicity Review AOPs .................................................. Only ...................... 15 15 16 Further development of the outlined AOPs to neurotoxicity ...................................................................... 20 17 18 References ................................................................................................................................................... 23 19 Appendix: Examples of the putative AOPs for neurotoxicity ................................................................... 28 20 21 I. Adverse Outcome Pathway on: Binding of antagonist to an NMDAR during synaptogenesis contributes 22 to impairment of learning and memory abilities ......................................................................................... 28 23 24 II. Adverse Outcome Pathway on: Binding of agonist to NMDA receptor causes excitotoxicity that 25 mediates neuronal cell death, contributing to reduction (or loss) of cognitive, sensory and motor function 26 27 .................................................................................................................................................................... 35 28 III. Adverse Outcome Pathway on: Binding of antagonist to GABA receptor results in hyperexcitability 29 A 30 and convulsions ........................................................................................................................................... 42 31 IV. Adverse Outcome Pathway on: Binding of Pyrethroids to Voltage-gated Sodium Channels induces 32 33 acute neurotoxicity ...................................................................................................................................... 47 34 V. Adverse Outcome Pathway on: Binding of certain organophosphates to NTE results in delayed 35 36 neuropathy .................................................................................................................................................. 56 37 VI. Adverse Outcome Pathway on: Impairment of learning and memory induced by binding of 38 39 electrophilic chemicals to SH(thiol)-group of proteins and non-protein molecules in neuronal and glial 40 cells during development ............................................................................................................................ 63 41 42 VII. Adverse Outcome Pathway on: Binding of inhibitors to the mitochondrial respiration chain complex 43 I, II, III or IV or interaction of uncouplers with oxidative phosphorylation decreases or blocks ATP 44 production resulting in neurodegeneration. ..............................................................................................
Load more

Recommended publications
  • Picrotoxin-Like Channel Blockers of GABAA Receptors
    COMMENTARY Picrotoxin-like channel blockers of GABAA receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 icrotoxin (PTX) is the prototypic vous system. Instead of an acetylcholine antagonist of GABAA receptors (ACh) target, the cage convulsants are (GABARs), the primary media- noncompetitive GABAR antagonists act- tors of inhibitory neurotransmis- ing at the PTX site: they inhibit GABAR Psion (rapid and tonic) in the nervous currents and synapses in mammalian neu- system. Picrotoxinin (Fig. 1A), the active rons and inhibit [3H]dihydropicrotoxinin ingredient in this plant convulsant, struc- binding to GABAR sites in brain mem- turally does not resemble GABA, a sim- branes (7, 9). A potent example, t-butyl ple, small amino acid, but it is a polycylic bicyclophosphorothionate, is a major re- compound with no nitrogen atom. The search tool used to assay GABARs by compound somehow prevents ion flow radio-ligand binding (10). through the chloride channel activated by This drug target appears to be the site GABA in the GABAR, a member of the of action of the experimental convulsant cys-loop, ligand-gated ion channel super- pentylenetetrazol (1, 4) and numerous family. Unlike the competitive GABAR polychlorinated hydrocarbon insecticides, antagonist bicuculline, PTX is clearly a including dieldrin, lindane, and fipronil, noncompetitive antagonist (NCA), acting compounds that have been applied in not at the GABA recognition site but per- huge amounts to the environment with haps within the ion channel. Thus PTX major agricultural economic impact (2). ͞ appears to be an excellent example of al- Some of the other potent toxicants insec- losteric modulation, which is extremely ticides were also radiolabeled and used to important in protein function in general characterize receptor action, allowing and especially for GABAR (1).
    [Show full text]
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
    [Show full text]
  • XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian's, Malta
    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian's, Malta To cite this article: (2015) XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian's, Malta, Clinical Toxicology, 53:4, 233-403, DOI: 10.3109/15563650.2015.1024953 To link to this article: http://dx.doi.org/10.3109/15563650.2015.1024953 Published online: 26 Mar 2015. Submit your article to this journal Article views: 3422 View related articles View Crossmark data Citing articles: 2 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 Download by: [UPSTATE Medical University Health Sciences Library] Date: 28 December 2016, At: 10:31 Clinical Toxicology (2015), 53, 233–403 Copyright © 2015 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2015.1024953 ABSTRACTS XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 26–29 May 2015, St Julian ’ s, Malta 1. Modelling dose-concentration-response Introduction: The American Association of Poison Control Cen- ters (AAPCC) published its fi rst annual report in 1983. Call data Ursula Gundert-Remy from sixteen US poison centers was chronicled in that report. Seven submitted data for the entire year. By July 2000, 63 centers Institute for Clinical Pharmacology and Toxicology, Charit é were part of the national poison center system, but only 59 submit- Medical School, Berlin, Germany ted data for the full year.
    [Show full text]
  • The Nutrition and Food Web Archive Medical Terminology Book
    The Nutrition and Food Web Archive Medical Terminology Book www.nafwa.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/00284.18 A1 Parker Et Al
    US 2011 002841 8A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/00284.18 A1 Parker et al. (43) Pub. Date: Feb. 3, 2011 (54) USE OF GABBA RECEPTOR ANTAGONISTS Publication Classification FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCATED (51) Int. Cl. WITH EXCESSIVE SLEEPINESS A63L/7028 (2006.01) A 6LX 3/557 (2006.01) (75) Inventors: Kathy P. Parker, Rochester, NY A63L/335 (2006.01) (US); David B. Rye, Dunwoody, A63L/4355 (2006.01) GA (US); Andrew Jenkins, A63L/047 (2006.01) Decatur, GA (US) A6IP 25/00 (2006.01) Correspondence Address: (52) U.S. Cl. ........... 514/29: 514/220; 514/450, 514/291; FISH & RICHARDSON P.C. (AT) 5147738 P.O BOX 1022 Minneapolis, MN 55440-1022 (US) (57) ABSTRACT (73) Assignee: Emory University, Atlanta, GA GABA receptor mediated hypersomnia can be treated by (US) administering a GABA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and (21) Appl. No.: 12/922,044 oenanthotoxin). In some embodiments, the GABA receptor antagonist is flumazenil or clarithromycin. The GABA (22) PCT Filed: Mar. 12, 2009 receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narco (86). PCT No.: PCT/USO9/37034 lepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hyperSonmia; endozepine related S371 (c)(1), recurrent stupor; and amphetamine resistant hyperSonmia), (2), (4) Date: Sep. 10, 2010 and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and Related U.S. Application Data hypersomnia (e.g., idiopathic hypersomnia; recurrent hyper (60) Provisional application No.
    [Show full text]
  • TRIDIONE® (Trimethadione) Tablets
    TRIDIONE® (trimethadione) Tablets BECAUSE OF ITS POTENTIAL TO PRODUCE FETAL MALFORMATIONS AND SERIOUS SIDE EFFECTS, TRIDIONE (trimethadione) SHOULD ONLY BE UTILIZED WHEN OTHER LESS TOXIC DRUGS HAVE BEEN FOUND INEFFECTIVE IN CONTROLLING PETIT MAL SEIZURES. DESCRIPTION TRIDIONE (trimethadione) is an antiepileptic agent. An oxazolidinedione compound, it is chemically identified as 3,5,5-trimethyloxozolidine-2,4-dione, and has the following structural formula: TRIDIONE is a synthetic, water-soluble, white, crystalline powder. It is supplied in tablets for oral use only. Inactive Ingredients 150 mg Dulcet Tablet: Corn starch, lactose, magnesium stearate, magnesium trisilicate, sucrose and natural/synthetic flavor. CLINICAL PHARMACOLOGY TRIDIONE has been shown to prevent pentylenetetrazol-induced and thujone-induced seizures in experimental animals; the drug has a less marked effect on seizures induced by picrotoxin, procaine, cocaine, or strychnine. Unlike the hydantoins and antiepileptic barbiturates, TRIDIONE does not modify the maximal seizure pattern in patients undergoing electroconvulsive therapy. TRIDIONE has a sedative effect that may increase to the point of ataxia when excessive doses are used. A toxic dose of the drug in animals (approximately 2 g/kg) produced sleep, unconsciousness, and respiratory depression. Trimethadione is rapidly absorbed from the gastrointestinal tract. It is demethylated by liver microsomes to the active metabolite, dimethadione. Approximately 3% of a daily dose of TRIDIONE is recovered in the urine as unchanged drug. The majority of trimethadione is excreted slowly by the kidney in the form of dimethadione. INDICATIONS TRIDIONE (trimethadione) is indicated for the control of petit mal seizures that are refractory to treatment with other drugs. CONTRAINDICATIONS TRIDIONE is contraindicated in patients with a known hypersensitivity to the drug.
    [Show full text]
  • 1-Iodo-1-Pentyne
    MIAMI UNIVERSITY-THE GRADUATE SCHOOL CERTIFICATE FOR APPROVING THE DISSERTATION We hereby approve the Dissertation of Lizhi Zhu Candidate for the Degree: Doctor of Philosophy ________________________________ Robert E. Minto, Director ________________________________ John R. Grunwell, Reader ________________________________ John F. Sebastian, Reader ________________________________ Ann E. Hagerman, Reader ________________________________ Richard E. Lee, Graduate School Representative ABSTRACT INVESTIGATING THE BIOSYNTHESIS OF POLYACETYLENES: SYNTHESIS OF DEUTERATED LINOLEIC ACIDS & MECHANISM STUDIES OF DMDS ADDITION TO 1,4-ENYNES By Lizhi Zhu A wide range of polyacetylenic natural products possess antimicrobial, antitumor, and insecticidal properties. The biosyntheses of these natural products are widely distributed among fungi, algae, marine sponges, and higher plants. As details of the biosyntheses of these intriguing compounds remains scarce, it remains important to develop molecular probes and analytical methods to study polyacetylene secondary metabolism. An effective pathway to prepare selectively deuterium-labeled linoleic acids was developed. By this Pd-catalyzed method, deuterium can be easily introduced into the vinyl position providing deuterolinoleates with very high isotopic purity. This method also provides a general route for the construction of 1,4-diene derivatives with different chain lengths and 1,4-diene locations. Linoleic acid derivatives (12-d, 13-d and 16,16,17,17,18,18,18-d7) were synthesized according to this method. A stereoselective synthesis of methyl (14Z)- and (14E)-dehydrocrepenynate was achieved in five to six steps that employed Pd-catalyzed cross-coupling reactions to construct the double bonds between C14 and C15. Compared with earlier methods, the improved syntheses are more convenient (no spinning band distillations or GLC separation of diastereomers were necessary) and higher Z/E ratios were obtained.
    [Show full text]
  • Fall TNP Herbals.Pptx
    8/18/14 Introduc?on to Objecves Herbal Medicine ● Discuss history and role of psychedelic herbs Part II: Psychedelics, in medicine and illness. Legal Highs, and ● List herbs used as emerging legal and illicit Herbal Poisons drugs of abuse. ● Associate main plant and fungal families with Jason Schoneman RN, MS, AGCNS-BC representave poisonous compounds. The University of Texas at Aus?n ● Discuss clinical management of main toxic Schultes et al., 1992 compounds. Psychedelics Sacraments: spiritual tools or sacred medicine by non-Western cultures vs. Dangerous drugs of abuse vs. Research and clinical tools for mental and physical http://waynesword.palomar.edu/ww0703.htm disorders History History ● Shamanic divinaon ○ S;mulus for spirituality/religion http://orderofthesacredspiral.blogspot.com/2012/06/t- mckenna-on-psilocybin.html http://www.cosmicelk.net/Chukchidirections.htm 1 8/18/14 History History http://www.10zenmonkeys.com/2007/01/10/hallucinogenic- weapons-the-other-chemical-warfare/ http://rebloggy.com/post/love-music-hippie-psychedelic- woodstock http://fineartamerica.com/featured/misterio-profundo-pablo- amaringo.html History ● Psychotherapy ○ 20th century: un;l 1971 ● Recreaonal ○ S;mulus of U.S. cultural revolu;on http://qsciences.digi-info-broker.com http://www.uspharmacist.com/content/d/feature/c/38031/ http://en.wikipedia.org/nervous_system 2 8/18/14 Main Groups Main Groups Tryptamines LSD, Psilocybin, DMT, Ibogaine Other Ayahuasca, Fly agaric Phenethylamines MDMA, Mescaline, Myristicin Pseudo-hallucinogen Cannabis Dissociative
    [Show full text]
  • Is Palatability of a Root-Hemiparasitic Plant Influenced by Its Host Species?
    Oecologia (2005) 146: 227–233 DOI 10.1007/s00442-005-0192-3 PLANTANIMALINTERACTIONS Martin Scha¨dler Æ Mareike Roeder Æ Roland Brandl Diethart Matthies Is palatability of a root-hemiparasitic plant influenced by its host species? Received: 16 November 2004 / Accepted: 21 June 2005 / Published online: 19 July 2005 Ó Springer-Verlag 2005 Abstract Palatability of parasitic plants may be influ- Introduction enced by their host species, because the parasites take up nutrients and secondary compounds from the hosts. If Parasitic plants attack shoots or roots of other plants and parasitic plants acquired the full spectrum of secondary take up water, nutrients and solutes from the hosts by compounds from their host, one would expect a corre- means of specialized contact organs (haustoria, Kuijt lation between host and parasite palatability. We 1969). About 1% of all plants are parasitic and parasitic examined the palatability of leaves of the root-hemi- plants are common components of many plant commu- parasite Melampyrum arvense grown with different host nities (Molau 1995). The majority of parasitic plants are plants and the palatability of these host plants for two actually hemiparasites that have green leaves and are generalist herbivores, the caterpillar of Spodoptera lit- able to photosynthesize (Kuijt 1969). Parasitic plants can toralis and the slug Arion lusitanicus. We used 19 species drastically reduce the growth of their host plants and of host plants from 11 families that are known to con- some are important agricultural pests (Parker and Riches tain a wide spectrum of anti-herbivore compounds. 1993; Pennings and Callaway 2002). Because parasitic Growth of M.
    [Show full text]
  • Developmental Deltamethrin: Effects on Cognition, Neurotransmitter Systems, Inflammatory Cytokines and Cell Death
    Developmental deltamethrin: Effects on cognition, neurotransmitter systems, inflammatory cytokines and cell death A dissertation submitted to the Graduate School of the University of Cincinnati In partial fulfillment of the requirements for the degree of Doctor of Philosophy In the Neuroscience Graduate Program of the College of Medicine By Emily Pitzer B.S. Westminster College April 2020 Dissertation Committee: Steve Danzer, Ph.D. Mary Beth Genter, Ph.D. Gary Gudelsky, Ph.D. Kimberly Yolton, Ph.D. Charles Vorhees, Ph.D. (Advisor) Michael Williams, Ph.D. (Chair) ABSTRACT Deltamethrin (DLM) is a Type II pyrethroid pesticide and is more widely used with the elimination of organophosphate pesticides. Epidemiological studies have linked elevated levels of pyrethroid metabolites in urine during development with neurological disorders, raising concern for the safety of children exposed to these agents. Few animal studies have explored the effects or mechanisms of DLM-induced deficits in behavior and cognition after developmental exposure. The aim of the present work is to examine the long-term effects of developmental (postnatal day (P) 3-20) DLM exposure in Sprague-Dawley rats on behavior, cognition, and cellular outcomes. First, the developmental effects of early DLM exposure on allocentric and egocentric learning and memory, locomotor activity, startle, conditioned freezing, and anxiety-like behaviors were assessed. The developmental effects of DLM on long-term potentiation (LTP) at P25-35, on adult dopamine (DA) release, monoamine levels, and mRNA levels of receptors/transporters/channels were then determined. In follow-up experiments, adult LTP, hippocampal glutamate release, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining for cell death, as well as DA and glutamate receptors, proinflammatory cytokines, and caspase-3 for protein expression were assessed.
    [Show full text]
  • Cicuta Douglasii) Tubers
    Toxicon 108 (2015) 11e14 Contents lists available at ScienceDirect Toxicon journal homepage: www.elsevier.com/locate/toxicon Short communication The non-competitive blockade of GABAA receptors by an aqueous extract of water hemlock (Cicuta douglasii) tubers * Benedict T. Green a, , Camila Goulart b, 1, Kevin D. Welch a, James A. Pfister a, Isabelle McCollum a, Dale R. Gardner a a Poisonous Plant Research Laboratory, Agricultural Research Service, United States Department of Agriculture, Logan, UT, USA b Graduate Program in Animal Science, Universidade Federal de Goias, Goiania,^ Goias, Brazil article info abstract Article history: Water hemlocks (Cicuta spp.) are acutely toxic members of the Umbellierae family; the toxicity is due to Received 22 July 2015 the presence of C17-polyacetylenes such as cicutoxin. There is only limited evidence of noncompetitive Received in revised form antagonism by C17-polyacetylenes at GABAA receptors. In this work with WSS-1 cells, we documented 9 September 2015 the noncompetitive blockade of GABA receptors by an aqueous extract of water hemlock (Cicuta dou- Accepted 14 September 2015 A glasii) and modulated the actions of the extract with a pretreatment of 10 mM midazolam. Available online 28 September 2015 Published by Elsevier Ltd. Keywords: Water hemlock Cicutoxin C17-polyacetylenes Benzodiazepines Barbiturates Midazolam Water hemlocks (Cicuta spp.) are acutely toxic members of the antagonists of the GABAA receptor by binding to the picrotoxin Umbellierae, or carrot family, that grow in wet habitats such as binding site within the chloride channel to block ion flow through streambeds or marshlands, and have been considered one of the the channel (Ratra et al., 2001; Chen et al., 2006; 2011; Olsen, most toxic plants of North America for many years (Kingsbury, 2006).
    [Show full text]